MedTrace Logo

Effect of Galantamine on Short-term Abstinence

NCT01669538 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 98

Last updated 2019-02-15

Study results available
· View outcomes & findings →

Summary

This is a randomized, double-blind, placebo-controlled study to test whether a medication called galantamine (Brand Name: Razadyne) will help smokers quit and whether it reduces cognitive problems that smokers experience during a quit attempt.

Conditions

  • Tobacco Use Disorder

Interventions

DRUG

Galantamine

DRUG

Placebo

Sponsors & Collaborators

  • National Institutes of Health (NIH)

    collaborator NIH

  • National Cancer Institute (NCI)

    collaborator NIH

  • National Center for Research Resources (NCRR)

    collaborator NIH

  • National Institute on Drug Abuse (NIDA)

    collaborator NIH

  • University of Pennsylvania

    lead OTHER

Principal Investigators

  • Rebecca Ashare, Ph.D. · University of Pennsylvania

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-08-31
Primary Completion
2017-11-30
Completion
2017-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01669538 on ClinicalTrials.gov